Smoking history is more predictive of survival benefit from erlotinib for patients with non-small cell lung cancer (NSCLC) than EGFR expression

7033 Background: Erlotinib (E, [Tarceva]) is an orally available, reversible inhibitor of the HER1/EGFR tyrosine kinase that has recently been approved by the FDA for the treatment of patients (pts...